Imaging and Biomarker Core

摘要 影像学和生物标志物（IB）核心将通过神经影像学表征临床核心中的受试者 和流体生物标志物分析，符合现行标准。另一个重点是严格描述 参与者的地形表型，并将此信息与认知，流体生物标志物，遗传， 和神经病理学的数据。核心还将提供一个信息结构， 咨询专业知识，向ADRC附属研究和研究者提供成像数据。 许多UW ADRC附属研究需要具有良好成像特征的人类受试者， 流体生物标志物。MRI成像将在所有正常认知、MCI和轻度AD参与者中获得。 临床和本土研究和资源（NRRC）核心。我们将描述我们的临床核心队列， 一|不|N分类，主要使用CSF生物标志物（A，T）和MRI（N）成像。IB核心将协调 在ADRC附属项目中进行PET扫描或在临床核心中共同招募附属受试者，以确保临床核心 对受试者进行PET扫描。我们提供规划和分析PET分子的专业知识 影像学研究 附属研究正在调查AD的具体候选机制，以及是否以及为什么， AD中固有的不同病理机制对大脑皮层具有不同的影响模式。为 在这些研究中，脑空间是AD的其他生物标志物的整合点。我们组织了IB 核心及其与临床和神经病理学核心的相互作用， 从成像数据确定的，作为表型特征，与认知域、流体、血液和/或体液一起沿着， 生物标记和遗传数据。我们将测量皮质退化，以及皮质保留，在一组 这些脑区代表了参与AD的范围和可变性。的另一个重要方面 认知变异性是由给定程度的 认知弹性（cognitive resilience）因此，我们还将从以下几个方面提取认知弹性的指标： 认知和解剖数据，作为另一个表型维度。我们将提供咨询专业知识， 信息学/机器学习、图像分析和统计用于这些数据的描述和分析。 我们还构建了核心，以支持在死亡者中进行相同的多学科表型分析， 来验尸的临床队列。我们将进行离体MRI，并进行结构测量 如在体内研究中一样。我们将从活体成像的同一区域采集组织样本， 参与者我们将计算类似的弹性措施。离体MRI还将实现有针对性的采样 尸检时MRI明显异常，并将神经病理学数据映射到标准解剖空间。

Abstract The Imaging and Biomarker (IB) Core will characterize participants in the Clinical Core through neuroimaging and fluid biomarker analysis, in conformity with prevailing standards. A further focus is to rigorously describe topographic phenotypes of the participants and to link this information to cognitive, fluid biomarker, genetic, and neuropathologic data generated by the Center. The Core will also provide an information architecture and consulting expertise to represent the imaging data to ADRC-affiliated studies and investigators. Many UW ADRC-affiliated studies require human subjects who are well-characterized with imaging and fluid biomarkers. MRI imaging will be obtained on all normal cognition, MCI, and mild AD participants in the Clinical and Native Research and Resource (NRRC) Cores. We will characterize our Clinical Core cohort with A|T|N classification, primarily with CSF biomarkers (A, T) and MRI (N) imaging. The IB Core will coordinate PET scans in ADRC affiliate projects or co-enroll affiliate subjects in the Clinical Core to ensure Clinical Core subjects have PET scanning performed. We provide expertise in planning and analyzing PET molecular imaging studies. Affiliated studies are investigating specific candidate mechanisms of AD, as well as whether, and why, different pathological mechanisms inherent in AD have differing patterns of impact over the cerebral cortex. For such studies, the brain space is a point of integration of the other biomarkers of AD. We have organized the IB Core and its interactions with the Clinical and Neuropathology Cores such that topographical heterogeneity, determined from imaging data, is incorporated as a phenotypic characteristic, along with cognitive domain, fluid biomarker, and genetic data. We will measure cortical degeneration, as well as cortical sparing, across a set of brain regions that represent the range and variability of involvement in AD. Another important aspect of cognitive variability is the relationship of the degree of cognitive impairment that results from a given degree of neurodegeneration (cognitive resilience). Thus we will also extract measures of cognitive resilience from cognitive and anatomic data, as another phenotypic dimension. We will provide consulting expertise in informatics/machine learning, image analysis and statistics for the description and analysis of these data. We have also structured the Core to support the same multidisciplinary phenotyping in decedents from the Clinical cohort who come to autopsy. We will perform ex vivo MRI in all, and process structural measures as in the in vivo studies. We will sample tissue from the same regions that we target with imaging in living participants. We will calculate analogous resilience measures. Ex vivo MRI will also enable targeted sampling of MRI-apparent abnormalities at autopsy and mapping neuropathologic data into standard anatomical space.